<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biocryst Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc</link>
<description>Latest news and press releases for Biocryst Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biocryst-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354ba678dffbe2df0e52ea.webp</url>
<title>Biocryst Pharmaceuticals Inc</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc</link>
</image>
<item>
<title>BioCryst to Report First Quarter 2026 Financial Results on May 6</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-to-report-first-quarter-2026-financial-results-on-may-6</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-to-report-first-quarter-2026-financial-results-on-may-6</guid>
<pubDate>Wed, 15 Apr 2026 11:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A</description>
</item>
<item>
<title>BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-appoints-sandeep-m-menon-chief-research-and-development-officer</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-appoints-sandeep-m-menon-chief-research-and-development-officer</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April</description>
</item>
<item>
<title>BioCryst Reports Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-reports-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-reports-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European</description>
</item>
<item>
<title>BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-hae-data-orladeyo-120000783</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-hae-data-orladeyo-120000783</guid>
<pubDate>Wed, 11 Feb 2026 12:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia from February 27-March 2, 2026. Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targete</description>
</item>
<item>
<title>BioCryst to Report Fourth Quarter 2025 Financial Results on February 26</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-report-fourth-quarter-2025-120100867</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-report-fourth-quarter-2025-120100867</guid>
<pubDate>Thu, 05 Feb 2026 12:01:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers</description>
</item>
<item>
<title>BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-completes-acquisition-astria-therapeutics-140000315</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-completes-acquisition-astria-therapeutics-140000315</guid>
<pubDate>Fri, 23 Jan 2026 14:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to</description>
</item>
<item>
<title>BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema </title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-completes-acquisition-astria-therapeutics-expanding-leadership-hereditary</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-completes-acquisition-astria-therapeutics-expanding-leadership-hereditary</guid>
<pubDate>Fri, 23 Jan 2026 05:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its</description>
</item>
<item>
<title>Astria Stockholders Vote to Approve Acquisition by BioCryst</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/astria-stockholders-vote-to-approve-acquisition-by-biocryst</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/astria-stockholders-vote-to-approve-acquisition-by-biocryst</guid>
<pubDate>Wed, 21 Jan 2026 21:00:00 GMT</pubDate>
<description>BOSTON, January 21, 2026--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the "Merger").</description>
</item>
<item>
<title>BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-announces-preliminary-full-year-2025-orladeyor-berotralstat-net-revenue-601</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-announces-preliminary-full-year-2025-orladeyor-berotralstat-net-revenue-601</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)–</description>
</item>
<item>
<title>BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-reports-inducement-grants-under-120100922</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-reports-inducement-grants-under-120100922</guid>
<pubDate>Tue, 06 Jan 2026 12:01:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee...</description>
</item>
<item>
<title>BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-44th-annual-j-120000170</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-44th-annual-j-120000170</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to...</description>
</item>
<item>
<title>BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-announces-fda-approval-orladeyor-berotralstat-oral-pellets-first-and-only</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-announces-fda-approval-orladeyor-berotralstat-oral-pellets-first-and-only</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method</description>
</item>
<item>
<title>BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-receives-early-termination-hsr-waiting-period-astria-acquisition-2025-12-03</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-receives-early-termination-hsr-waiting-period-astria-acquisition-2025-12-03</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early</description>
</item>
<item>
<title>Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/astria-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/astria-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>BOSTON, November 12, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-presents-new-data-acaai-highlighting-burden-hae-pediatric-patients-and</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-presents-new-data-acaai-highlighting-burden-hae-pediatric-patients-and</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral</description>
</item>
<item>
<title>BioCryst to Present at Upcoming Investor Conference</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-upcoming-investor-conference-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-upcoming-investor-conference-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to</description>
</item>
<item>
<title>BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating</description>
</item>
<item>
<title>BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-new-pediatric-hae-data-american-college-allergy-asthma-immunology</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-present-new-pediatric-hae-data-american-college-allergy-asthma-immunology</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present</description>
</item>
<item>
<title>BioCryst to Report Third Quarter 2025 Financial Results on November 3</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-report-third-quarter-2025-financial-results-november-3-2025-10-20</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-report-third-quarter-2025-financial-results-november-3-2025-10-20</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its</description>
</item>
<item>
<title>BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile</title>
<link>https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-acquire-astria-therapeutics-strengthening-presence-hae-transforming-growth-0</link>
<guid isPermaLink="true">https://6ix.com/company/biocryst-pharmaceuticals-inc/news/biocryst-acquire-astria-therapeutics-strengthening-presence-hae-transforming-growth-0</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – –</description>
</item>
</channel>
</rss>